Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Biosimilars Launches Strategy

Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched

MA Holder Theramex Has Plans For More EU Countries

  • News

Executive Summary

After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.

You may also be interested in...



Gedeon Richter Spends Most On Biosimilar R&D

Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.

Ligand Set For Partnership Opportunities After Completing On Pfenex

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Ligand Snaps Up Pfenex For Half A Billion

Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Scrip

Topics

Related Companies

Tags:
Biosimilars Launches Strategy
UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By